“Comparative Efficacy and Safety of Individual SGLT2 Inhibitors (Dapagliflozin, Empagliflozin, and Canagliflozin) on Kidney Function Decline in CKD: A Systematic Review and Network Meta-Analysis” (2025) Open Access Indonesian Journal of Medical Reviews, 5(6), pp. 1772–1789. doi:10.37275/oaijmr.v5i6.818.